Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN008 + TMZ + RT in newly diagnosed GBM
NCT02853565Phase 1Completed
- Sponsor
- CANbridge Pharmaceuticals Inc.
- Start
- Aug 2016
- Primary completion
- Sep 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of asunercept in glioblastoma multiforme (GBM), sponsored by CANbridge Pharmaceuticals Inc. Primary endpoint: Incidence of Treatment-Emergent Adverse Events up to 2 years. Started Aug 2016; status: completed.
02
Drugs
asunercept
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02853565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02853565.